This clinical trial is focused on studying the effects of a treatment called rapcabtagene autoleucel in people with a condition known as systemic lupus erythematosus (SLE), which is a disease where the immune system attacks the body’s own tissues. Specifically, the study targets those with a severe form of SLE that affects the kidneys, called lupus nephritis. The purpose of the study is to compare the effectiveness and safety of rapcabtagene autoleucel against the standard treatments currently used for this condition.
Participants in the study will receive either rapcabtagene autoleucel or one of the standard treatments, which may include medications like cyclophosphamide, voclosporin, belimumab, rituximab, mycophenolate mofetil, tacrolimus, or fludarabine phosphate. Rapcabtagene autoleucel is a type of cell therapy that involves modifying a person’s own immune cells to better fight the disease. The study will last for about a year, during which participants will be monitored to see how well the treatment works and to check for any side effects.
The study is designed to help researchers understand if rapcabtagene autoleucel can provide better outcomes for patients with lupus nephritis compared to the current standard treatments. Participants will be assessed for improvements in their condition and any changes in their health over the course of the study. This research aims to find more effective ways to manage and treat lupus nephritis, potentially offering new hope for those affected by this challenging condition.
Austria 
Czechia 
Denmark 
France 
Germany 
Hungary 
Italy 
Norway 
Poland 
Romania 
Spain 
Sweden 
The Netherlands 
